CN112521447A - Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with anti-aging effect - Google Patents
Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with anti-aging effect Download PDFInfo
- Publication number
- CN112521447A CN112521447A CN201911170311.1A CN201911170311A CN112521447A CN 112521447 A CN112521447 A CN 112521447A CN 201911170311 A CN201911170311 A CN 201911170311A CN 112521447 A CN112521447 A CN 112521447A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- compound
- formula
- fermentation product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 142
- 239000006041 probiotic Substances 0.000 title claims abstract description 95
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 95
- 238000000855 fermentation Methods 0.000 title claims abstract description 92
- 230000004151 fermentation Effects 0.000 title claims abstract description 92
- 150000001875 compounds Chemical class 0.000 title claims abstract description 84
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 51
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 19
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 18
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 16
- 244000268590 Euryale ferox Species 0.000 claims abstract description 14
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 14
- 241000234435 Lilium Species 0.000 claims abstract description 14
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 14
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 14
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 14
- 241001061264 Astragalus Species 0.000 claims abstract description 12
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 12
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 12
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000004347 Perilla Nutrition 0.000 claims abstract description 12
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 12
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 12
- 210000004233 talus Anatomy 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 244000124853 Perilla frutescens Species 0.000 claims abstract 3
- 239000000047 product Substances 0.000 claims description 72
- 239000000243 solution Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 19
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 10
- 229940039696 lactobacillus Drugs 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 7
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 238000002953 preparative HPLC Methods 0.000 claims description 6
- 230000003064 anti-oxidating effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000009758 senescence Effects 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 239000000178 monomer Substances 0.000 description 23
- 239000000284 extract Substances 0.000 description 21
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 18
- 102000019197 Superoxide Dismutase Human genes 0.000 description 18
- 108010012715 Superoxide dismutase Proteins 0.000 description 18
- 229940118019 malondialdehyde Drugs 0.000 description 18
- 230000032683 aging Effects 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000244206 Nematoda Species 0.000 description 15
- 230000006378 damage Effects 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 241000229722 Perilla <angiosperm> Species 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000003891 ferrous sulphate Nutrition 0.000 description 4
- 239000011790 ferrous sulphate Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- -1 Benzyl O-benzyl-N-(2,4-dimethoxybenzoyl)serylglycinate Chemical compound 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910001175 oxide dispersion-strengthened alloy Inorganic materials 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of biomedicine, and particularly discloses a compound, a traditional Chinese medicine probiotic fermentation product and application of the compound and the traditional Chinese medicine probiotic fermentation product in preparation of a medicine or a health-care product with an anti-aging effect. The traditional Chinese medicine probiotic fermentation product comprises a compound shown in a formula (I); the preparation method comprises the following steps: (1) taking the traditional Chinese medicine raw materials, and fermenting with probiotics to obtain fermentation liquor; (2) drying the fermentation liquor to obtain the traditional Chinese medicine probiotic fermentation product; the traditional Chinese medicine raw materials in the step (1) are traditional Chinese medicine raw materials comprising purple perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaf, mint and gorgon fruit. The compound shown in the formula (I) and the traditional Chinese medicine probiotic fermentation product have excellent effects of resisting oxidation and delaying senescence; can be used for preparing medicines and health products.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a compound, a traditional Chinese medicine probiotic fermentation product and application thereof in preparation of a medicine or a health-care product with an anti-aging effect.
Background
As a person ages, there are aging conditions such as white hair, tooth loss, muscular atrophy, angiosclerosis, slow sensory response, memory deterioration, and metabolic function decline. The phenomenon of irreversible functional decline and gradual death of various organs, tissues and cells in the body accompanying the increase of age is generally called aging of the body. The aging of the group has the cellular biology basis. During aging, cells of tissues and organs also undergo a gradual decline in morphological structure and physiological function. With the increase of age, the self-renewal and proliferation and differentiation abilities of cells are reduced, so that the damage of tissues and organs is difficult to repair, the normal physiological function is difficult to maintain, and the aging of the organism inevitably occurs. The problem of delaying aging needs to be explored and researched.
The understanding of the aging mechanism by the basic theory of traditional Chinese medicine is centered on the zang-fu organs, and the kidneys play an important role in the aging mechanism of traditional Chinese medicine. The selection of the antioxidant and anti-aging traditional Chinese medicines (including single traditional Chinese medicine, compound preparation and traditional Chinese medicine extract) not only accords with the comprehensive, early and long-term principles, but also depends on the actual condition of an individual and is in accordance with the condition of people. More than 2000 years ago, the earliest classic traditional Chinese medicine book, the "internal classic" in China, had records on the aging process of human beings. The records of Ling Shu and Tian Nian Ling are: for example, liver qi begins to decline in the fifty years old, liver lobes begin to thin, bile begins to decline, and the eyes begin to be unknown. Sixty years old, heart-qi begins to decline, so the patient feels good lying because of the sorrow of the heart-qi and the exhaustion of blood-qi. Seventy years old, spleen qi deficiency and dry skin. Eighty years old, the lung qi is too weak, the body is too strong and the body is too weak. Ninety years old, kidney qi scorching, and four zang organs with empty vessels.
The understanding of the aging mechanism by the basic theory of traditional Chinese medicine takes viscera as the core, and comprises theories of kidney deficiency aging, liver depression aging, spleen and stomach weakness aging, qi stagnation, blood stasis, phlegm turbidity aging and the like. The traditional Chinese medicine considers that the aging is mainly caused by kidney deficiency, spleen deficiency and qi and blood deficiency. Therefore, tonifying the kidney, strengthening the spleen and replenishing qi are basic ways of delaying senescence, and activating blood circulation to dissipate blood stasis is a main method of delaying senescence. Some Chinese medicines with the functions of invigorating vital energy, strengthening body resistance, consolidating constitution, tonifying and the like can achieve the aim of resisting aging by the principles of antioxidation and the like.
Lily is sweet and neutral in nature. It enters spleen, lung and heart meridians. The effect is as follows: tonify primordial qi, recover pulse to stop collapse, tonify spleen and lung, promote fluid production, and induce tranquilization. The main treatment is as follows: can be used for treating asthenia, collapse, cold limbs, weak pulse, spleen deficiency, anorexia, loose stool, short breath, asthenia, lung deficiency, asthma, cough due to body fluid deficiency, internal heat, diabetes, asthenia, palpitation, insomnia, sexual impotence, and cold womb; heart failure, cardiogenic shock. Has special effect on central nervous system, can balance brain excitation and inhibition, enhance physical strength, has remarkable antifatigue effect, and can improve mood and sleep condition, and eliminate general weakness and headache.
Mint, slightly sweet and warm in nature. It enters liver and kidney meridians. The effect is as follows: dispel wind-damp, tonify liver and kidney, strengthen tendons and bones, activate blood. The main treatment is as follows: arthralgia due to wind-cold-dampness, lumbago, gonalgia, flaccidity of bones and muscles, retardation of small children, weakness, traumatic injury, fracture, edema, beriberi, and pruritus vulvae. Is used for treating deficiency of liver and kidney, enhancing the resistance of the body to harmful stimulation factors, has good anti-fatigue effect, and can obviously improve the hypoxia tolerance and enhance the nonspecific immunity function of the body.
Gorgon fruit, sweet and warm in nature. It enters spleen and lung meridians. The effect is as follows: benefiting wei-defensive qi, consolidating superficial resistance, invigorating qi, invigorating yang, expelling toxin, promoting granulation, inducing diuresis, and relieving swelling. The main treatment is as follows: can be used for treating deficiency of qi, asthenia, anorexia, loose stool, collapse of middle-warmer energy, chronic diarrhea, rectocele, spontaneous perspiration, night sweat, blood deficiency, sallow complexion, dorsal furuncle, edema, internal heat, and diabetes. Has effects in invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, expelling pus, inducing diuresis, relieving swelling, enhancing immunity, promoting metabolism, lowering blood pressure, promoting urination, and inhibiting bacteria.
Ginkgo, semen Ginkgo, is sweet and neutral in nature. Has little toxicity. It enters heart and lung meridians. The effect is as follows: promoting blood circulation, removing blood stasis, dredging collaterals, relieving pain, astringing lung, relieving asthma, eliminating turbid pathogen, and reducing blood lipid. The main treatment is as follows: can be used for treating blood stasis, obstruction of collaterals, thoracic obstruction, cardialgia, apoplexy, hemiplegia, cough with asthma due to lung deficiency, and hyperlipidemia. As a traditional Chinese medicinal material, the Chinese medicinal composition is known for rejuvenation of the brain. Ginkgo is also a highly effective antioxidant. Experiments show that the gingko has higher efficiency in scavenging free radicals than vitamin E, and can effectively prevent high-fat cell membranes from being oxidized. Ginkgo biloba can restore the integrity of the cell membrane after the cells are destroyed by free radicals. In addition, ginkgo biloba may restore the ability of brain cells to receive signals from the nervous conduction system that direct the brain to perform work.
Other Chinese medicinal materials such as radix rehmanniae Preparata, radix asparagi, radix Ophiopogonis, radix Angelicae sinensis, cortex moutan, Notoginseng radix, radix Codonopsis, Atractylodis rhizoma, Ganoderma, fructus crataegi, Polygoni Multiflori radix, Poria, and rhizoma Polygonati can be used as antiaging agent. At present, a few reports exist on preparing lily, mint, ginkgo and gordon euryale seed into beverages or preparations. Although the methods have certain innovation, the traditional extraction and preparation methods are still adopted, so that the absorption and utilization rate of the human body is low, and certain limitations exist. The anti-aging drugs should not be indiscriminately used, and the application of the anti-aging drugs should meet the comprehensive, early and long-term principles, and the anti-aging drugs should be selected according to the individual's conditions from the actual point of view. Delaying aging is one of the key points and difficulties in the current life science research. Therefore, the development of antioxidant and anti-aging medicaments with independent intellectual property rights also becomes a hot point for the research and development of traditional Chinese medicines.
Disclosure of Invention
In view of the above, the present invention firstly provides a new compound, and further research shows that the new compound has antioxidant effect and anti-aging effect.
In addition, the invention also provides a traditional Chinese medicine probiotic fermentation product which also has the effects of resisting oxidation and delaying senescence.
In addition, the invention also provides a preparation method and application of the novel compound and a traditional Chinese medicine probiotic fermentation product.
The detailed technical scheme of the invention is as follows:
a compound of formula (I) or a pharmaceutically acceptable salt thereof;
the compound of formula (i) is named:
Benzyl O-benzyl-N-(2,4-dimethoxybenzoyl)serylglycinate。
preferably, the pharmaceutically acceptable salt is a pharmaceutically acceptable acid addition salt, wherein the acid is selected from the group consisting of: citric acid, tartaric acid, lactic acid, acetic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, pyruvic acid, fumaric acid, maleic acid, hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, and sulfuric acid.
The present invention provides a process for the preparation of a compound of formula (i) which comprises the steps of:
(1) taking the traditional Chinese medicine raw materials, and fermenting with probiotics to obtain fermentation liquor;
(2) drying the fermentation liquor to obtain a crude product;
(3) separating the crude product by chromatography to obtain a compound of formula (I);
the traditional Chinese medicine raw materials in the step (1) are traditional Chinese medicine raw materials comprising purple perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaf, mint and gorgon fruit;
the probiotics in the step (1) are selected from one or a mixture of more than two of bifidobacteria, lactobacillus liquid, bifidobacterium adolescentis or bifidobacterium infantis.
Preferably, the weight ratio of the perilla, the astragalus, the lily, the rhodiola rosea, the glossy privet fruit, the pseudo-ginseng, the ginkgo leaf, the mint and the gordon euryale seed in the traditional Chinese medicine raw materials in the step (1) is 1-5: 1-5: 1-5: 1-5: 1-5: 1-5: 1-5: 1-5: 1 to 5.
Most preferably, the weight ratio of the perilla, the astragalus, the lily, the rhodiola rosea, the glossy privet fruit, the pseudo-ginseng, the ginkgo leaf, the mint and the gordon euryale seed in the traditional Chinese medicine raw materials in the step (1) is 1: 1: 1: 1: 1: 1: 1: 1: 1. namely, the weight and the dosage of the traditional Chinese medicine raw materials are equal.
Preferably, the specific method of step (1) is: extracting the Chinese medicinal materials with water, and concentrating the extractive solution to obtain concentrated solution; then adding a fermentation nutrient into the concentrated solution; and then adding probiotics to ferment for 24-48 h under the conditions that the temperature is 35-40 ℃ and the pH is 6.5-7.5 to obtain fermentation liquor.
Further preferably, the amount of water used in the step (1) is 8-15 times of the amount of the traditional Chinese medicine raw materials.
Further preferably, the concentrated solution obtained in the step (1) is concentrated to 1/3-1/4 of the volume of the extracting solution.
Further preferably, the fermentation nutrient in step (1) comprises glucose 0.5% (weight/volume), yeast powder 0.1% (weight/volume), yeast extract 0.2% (weight/volume) and peptone 0.2% (weight/volume); the percentages are calculated on the volume of the concentrate.
Still more preferably, the nutrient for fermentation in step (1) further comprises 0.2% (w/v) potassium dihydrogen phosphate, 0.05% (w/v) magnesium sulfate, and 0.01% (w/v) ferrous sulfate; the percentages are calculated on the volume of the concentrate.
The probiotic is a combination of one selected from bifidobacterium and lactobacillus and one selected from bifidobacterium adolescentis and bifidobacterium infantis. The probiotics can be added in the form of dry powder, or can be activated by a conventional method and added in the form of bacteria liquid.
Preferably, the chromatographic technique described in step (3) is a preparative HPLC technique; the specific conditions of the preparative HPLC technique are as follows: adopting a reversed phase chromatographic column; selecting an ultraviolet detector, wherein the detection wavelength is 220-230 nm; using a trifluoroacetic acid aqueous solution with the volume percent of 0.1-0.3 as a mobile phase A, using a trifluoroacetic acid acetonitrile solution with the volume percent of 0.1-0.3 as a mobile phase B, wherein the mobile phase A: mobile phase B-78: 22; and (3) collecting the part corresponding to the chromatographic peak for 13.0-13.7 min, concentrating and drying to obtain the compound shown in the formula (I).
The invention also provides a traditional Chinese medicine probiotic fermentation product which comprises the compound shown in the formula (I).
The invention also provides a preparation method of the traditional Chinese medicine probiotic fermentation product, which comprises the following steps:
(1) taking the traditional Chinese medicine raw materials, and fermenting with probiotics to obtain fermentation liquor;
(2) drying the fermentation liquor to obtain the traditional Chinese medicine probiotic fermentation product;
the traditional Chinese medicine raw materials in the step (1) are traditional Chinese medicine raw materials comprising purple perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaf, mint and gorgon fruit;
the probiotics in the step (1) are selected from one or a mixture of more than two of bifidobacteria, lactobacillus liquid, bifidobacterium adolescentis or bifidobacterium infantis.
Preferably, the weight ratio of the perilla, the astragalus, the lily, the rhodiola rosea, the glossy privet fruit, the pseudo-ginseng, the ginkgo leaf, the mint and the gordon euryale seed in the traditional Chinese medicine raw materials in the step (1) is 1-5: 1-5: 1-5: 1-5: 1-5: 1-5: 1-5: 1-5: 1 to 5.
Most preferably, the weight ratio of the perilla, the astragalus, the lily, the rhodiola rosea, the glossy privet fruit, the pseudo-ginseng, the ginkgo leaf, the mint and the gordon euryale seed in the traditional Chinese medicine raw materials in the step (1) is 1: 1: 1: 1: 1: 1: 1: 1: 1. namely, the weight and the dosage of the traditional Chinese medicine raw materials are equal.
Preferably, the specific method of step (1) is: extracting the Chinese medicinal materials with water, and concentrating the extractive solution to obtain concentrated solution; then adding a fermentation nutrient into the concentrated solution; and then adding probiotics to ferment for 24-48 h under the conditions that the temperature is 35-40 ℃ and the pH is 6.5-7.5 to obtain fermentation liquor.
Further preferably, the amount of water used in the step (1) is 8-15 times of the amount of the traditional Chinese medicine raw materials.
Further preferably, the concentrated solution obtained in the step (1) is concentrated to 1/3-1/4 of the volume of the extracting solution.
Further preferably, the fermentation nutrient in step (1) comprises glucose 0.5% (weight/volume), yeast powder 0.1% (weight/volume), yeast extract 0.2% (weight/volume) and peptone 0.2% (weight/volume); the percentages are calculated on the volume of the concentrate.
Still more preferably, the nutrient for fermentation in step (1) further comprises 0.2% (w/v) potassium dihydrogen phosphate, 0.05% (w/v) magnesium sulfate, and 0.01% (w/v) ferrous sulfate; the percentages are calculated on the volume of the concentrate.
The probiotic is a combination of one selected from bifidobacterium and lactobacillus and one selected from bifidobacterium adolescentis and bifidobacterium infantis. The probiotics can be added in the form of dry powder, or can be activated by a conventional method and added in the form of bacteria liquid.
The invention also provides application of the compound of the formula (I) or medicinal salt thereof or a traditional Chinese medicine probiotic fermentation product in preparation of medicines or health-care products.
Preferably, the medicament has an anti-oxidation effect and/or an anti-aging effect; the health care product has an anti-oxidation effect and/or an anti-aging effect.
Preferably, the medicine or health care product contains a compound shown in the formula (I) or a medicinal salt thereof or a traditional Chinese medicine probiotic fermentation product and a carrier; the mass fraction of the compound of formula (I) or the medicinal salt thereof or the traditional Chinese medicine probiotic fermentation product is 5-95%.
Further preferably, the carrier comprises at least one of a solvent, a polymer and a liposome. Still further preferably, the solvent includes, but is not limited to, water, physiological saline, and other non-aqueous solvents. Still further preferably, the polymer includes, but is not limited to, polylysine, polyethyleneimine and modifications thereof, chitosan, polylactic acid, gelatin. Still further preferably, the liposome may be, but is not limited to, cholesterol, soy lecithin, egg yolk lecithin.
Even more preferably, the carrier further comprises one or more of a diluent and an excipient. Specifically, the diluent includes one or more of starches, sugars, celluloses and inorganic salts. Specifically, the excipient comprises one or more of a binder, a filler, a lubricant in a tablet, a matrix part in a semisolid preparation ointment or cream, a preservative in a liquid preparation, an antioxidant, a flavoring agent, an aromatic agent, a cosolvent, an emulsifier and a coloring agent.
Further preferably, the mass fraction of the compound of formula (I) or the pharmaceutically acceptable salt thereof or the traditional Chinese medicine probiotic fermentation product is 10-90%, 15-85% or 30-80%.
Preferably, the health product or the medicine is in the form of tablet, capsule, powder, granule, pill, syrup, solution, suspension or aerosol.
Preferably, the health product is in the form of gel or water.
Further preferably, the health product further comprises an auxiliary material matrix, wherein the auxiliary material matrix comprises one or more of monosaccharide, oligosaccharide, polysaccharide, amino acid, preservative and pH regulator.
Has the advantages that: (1) the invention provides a brand-new compound shown in formula (I), a traditional Chinese medicine probiotic fermentation product and a preparation method thereof; the compound of the formula (I) and the traditional Chinese medicine probiotic fermentation product have excellent effects of resisting oxidation and delaying senescence; can be used for preparing medicines and health products; (2) experiments show that the traditional Chinese medicine probiotic metabolite can obviously improve oxidative damage caused by D-galactose induction, obviously improve the activities of SOD, GSH-Px and T-AOC in mouse serum and liver, reduce the MDA content of lipid peroxides in mouse serum and liver, and improve the antioxidant capacity of mice.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only drawings of some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
FIG. 1 shows the mass spectrum of a compound of formula (I) according to the invention.
FIG. 2 shows a hydrogen spectrum of a compound of formula (I) according to the invention.
FIG. 3 shows the carbon spectrum of the compound of formula (I) according to the invention.
FIG. 4 is a graph showing the measurement of the activity of probiotic fermented products of Chinese herbs and monomeric compounds having the structure of formula (I) on mouse serum GSH-Px.
FIG. 5 is a graph showing the measurement of the T-AOC activity of the fermented product of probiotic bacteria of Chinese traditional medicine and the monomeric compound with the structure of formula (I) on mouse serum.
FIG. 6 shows the measurement of SOD activity of mouse serum by probiotic fermented product of Chinese medicinal materials and monomer compound with formula (I).
FIG. 7 is a graph of the measurement of the mouse serum MDA content of the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure of formula (I).
FIG. 8 is a graph showing the measurement of the activity of probiotic fermented products of Chinese herbs and monomeric compounds of formula (I) on mouse liver GSH-Px.
FIG. 9 is a graph showing the measurement of the T-AOC activity of the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure of formula (I) on mouse liver.
FIG. 10 shows the measurement of SOD activity of mouse liver by fermented product of probiotic bacteria of Chinese medicinal materials and monomer compound of formula (I).
FIG. 11 is a graph of the measurement of the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure of formula (I) on the MDA content of the mouse liver.
FIG. 12 shows the effect of probiotic fermentation of Chinese herbs and the monomeric compound of formula (I) on the longevity of N2 C.elegans.
FIG. 13 effect of probiotic metabolites of traditional Chinese medicine on the survival rate of N2 C.elegans under oxidative stress conditions.
FIG. 14 Effect of traditional Chinese medicine probiotic metabolites on N2 C.elegans ROS content under oxidative stress conditions.
FIG. 15 effect of probiotic metabolites of traditional Chinese medicine on MDA activity of N2 caenorhabditis elegans under oxidative stress conditions.
FIG. 16 the effect of probiotic metabolites of traditional Chinese medicine on the SOD activity of N2 C.elegans under oxidative stress conditions.
Detailed Description
The technical solution of the present invention will be clearly and completely described with reference to the following examples. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
EXAMPLE 1 preparation of the Compound of formula (I)
(1) Extracting the traditional Chinese medicine raw materials with 10 times of water, soaking for 60 minutes, and performing ultrasonic extraction for 60 minutes; concentrating the extractive solution to 1/3 volume to obtain concentrated solution; then adding a fermentation nutrient into the concentrated solution; then adding probiotics, and fermenting for 36h under the conditions that the temperature is 37 ℃ and the pH value is 7.0 to obtain fermentation liquor;
(2) centrifuging the fermentation liquor at 8000r/min for 30min, removing precipitate, retaining supernatant, and freeze drying the supernatant to obtain crude product;
(3) separating the crude product by chromatography to obtain a compound of formula (I);
the traditional Chinese medicine raw materials in the step (1) are prepared from perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaf, mint and gordon euryale seed according to a weight ratio of 1: 1: 1: 1: 1: 1: 1: 1: 1 (namely the usage of the traditional Chinese medicine raw materials is equal);
the addition amount of the fermentation nutrient in the step (1) is calculated according to the volume of the concentrated solution: it comprises glucose 0.5% (weight/volume), yeast powder 0.1% (weight/volume), yeast extract 0.2% (weight/volume) and peptone 0.2% (weight/volume); potassium dihydrogen phosphate 0.2% (w/v), magnesium sulfate 0.05% (w/v), ferrous sulfate 0.01% (w/v);
the probiotics in the step (1) are lactobacillus dry powder and bifidobacterium infantis dry powder; calculated according to the volume of the concentrated solution, the addition amount of the lactobacillus dry powder is 5 percent (weight/volume), and the addition amount of the bifidobacterium infantis dry powder is 2 percent (weight/volume);
the chromatographic technique in the step (3) is a preparative HPLC technique; the specific conditions of the preparative HPLC technique are as follows: adopting an ODS (oxide dispersion strengthened) reversed-phase chromatographic column; selecting an ultraviolet detector, wherein the detection wavelength is 220 nm; using a 0.2 volume percent trifluoroacetic acid aqueous solution as a mobile phase A, using a 0.2 volume percent trifluoroacetic acid acetonitrile solution as a mobile phase B, wherein the ratio of the mobile phase A: mobile phase B-78: 22; and (3) collecting the part corresponding to the chromatographic peak for 13.0-13.7 min, concentrating and drying to obtain the compound shown in the formula (I).
The mass spectrum, hydrogen spectrum and carbon spectrum data of the compound of the formula (I) are as follows (the specific spectrogram is shown in figures 1-3):
mass spectrometry data show [ M + Na [)]+529.2, molecular formula C28H30N2O7,1H NMR(500MHz,DMSO)δ:8.64(t,1H),8.55(d,1H),7.92(d,1H),7.31(m,10H),6.68(m,2H),5.12(s,2H),4.75(m,1H),4.51(s,2H),3.95(d,2H),3.56(m,2H),3.37(s,6H),3.07(m,1H).13C NMR(126MHz,DMSO)δ:170.26,169.52,163.68,163.25,158.98,138.16,135.87,132.83,128.40,128.21,128.05,127.91,127.44,127.40,113.69,105.97,98.68,72.13,70.09,65.88,56.25,55.57,52.82,40.94.
The Benzyl O-Benzyl-N- (2, 4-dimethoxybenzyl) seriylgylcetate prepared by the method can be confirmed to be obtained by mass spectrum, hydrogen spectrum and carbon spectrum analysis.
Example 2 preparation of traditional Chinese medicine probiotic fermentation product
(1) Extracting the traditional Chinese medicine raw materials with 10 times of water, soaking for 60 minutes, and performing ultrasonic extraction for 60 minutes; concentrating the extractive solution to 1/3 volume to obtain concentrated solution; then adding a fermentation nutrient into the concentrated solution; then adding probiotics, and fermenting for 36h under the conditions that the temperature is 37 ℃ and the pH value is 7.0 to obtain fermentation liquor;
(2) centrifuging the fermentation liquor at 8000r/min for 30min, removing precipitate, retaining supernatant, and freeze drying the supernatant to obtain traditional Chinese medicine probiotic fermentation product;
the traditional Chinese medicine raw materials in the step (1) are prepared from perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaf, mint and gordon euryale seed according to a weight ratio of 1: 1: 1: 1: 1: 1: 1: 1: 1 (namely the usage of the traditional Chinese medicine raw materials is equal);
the addition amount of the fermentation nutrient in the step (1) is calculated according to the volume of the concentrated solution: it comprises glucose 0.5% (weight/volume), yeast powder 0.1% (weight/volume), yeast extract 0.2% (weight/volume) and peptone 0.2% (weight/volume); potassium dihydrogen phosphate 0.2% (w/v), magnesium sulfate 0.05% (w/v), ferrous sulfate 0.01% (w/v);
the probiotics in the step (1) are lactobacillus dry powder and bifidobacterium infantis dry powder; calculated by the volume of the concentrated solution, the addition amount of the lactobacillus dry powder is 5 percent (weight/volume), and the addition amount of the bifidobacterium infantis dry powder is 2 percent (weight/volume).
Comparative example 1 Chinese medicinal extract
Extracting the traditional Chinese medicine raw materials with 10 times of water, soaking for 60 minutes, and performing ultrasonic extraction for 60 minutes; concentrating and drying the extract to obtain the traditional Chinese medicine extract. The traditional Chinese medicine raw materials comprise perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaves, mint and gordon euryale seed according to a weight ratio of 1: 1: 1: 1: 1: 1: 1: 1: 1 (namely the dosage of the traditional Chinese medicine raw materials is equal).
Experimental example 1 experiment of oxidative damage of mice induced by D-galactose caused by fermented product of probiotic bacteria of Chinese medicinal herbs and monomeric compound having structure of formula (I)
(1) Grouping and feeding animals
Taking 70 healthy mice, feeding at 18-22 deg.C under natural illumination, and feeding with common feed for 5 d. Randomly dividing mice into 5 groups, (a normal Control group (Control), a model Control group (DG), a traditional Chinese medicine extract group (TCM) prepared in a comparative example 1, a traditional Chinese medicine probiotic fermentation product group (TCMPM) prepared in an example 2 and a monomer compound group (TPMSC) with a structure of a formula (I), performing abdominal injection of 700 mg/(kg.d) D-galactose on the rest groups except the normal Control group to establish an oxidative damage model, performing intragastric perfusion on the traditional Chinese medicine extract group, the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of the formula (I) according to the dose of 200 mg/(kg.d) to obtain corresponding compounds, performing injection of physiological saline with the same volume to obtain distilled water with the same volume to perform intragastric perfusion for 1 time by weighing 2D, continuously taking 28D, taking blood from eyeballs to kill the mice, and measuring the superoxide dismutase (SOD) activity in serum and livers, Glutathione peroxidase (GSH-Px) activity, Malondialdehyde (MDA) content and total antioxidant capacity (T-AOC), and the in vivo antioxidant activity of traditional Chinese medicine extract, traditional Chinese medicine probiotic fermentation product and monomer compound with formula (I) structure is studied.
(2) Sample index detection
After the mice are subjected to last 1d gastric lavage, fasting is carried out for 12h, blood is taken from eye sockets, centrifugation is carried out for 20min at 5000r/min, serum is separated, supernatant is taken, and the MDA content, GSH-Px, SOD and T-AOC activity of the serum are detected according to the kit instructions. Dissecting a mouse, quickly taking out the liver, washing with normal saline, removing water by using absorbent paper, weighing 0.5g of liver tissue, placing the liver tissue in a homogenizer, adding 10 times volume of precooled normal saline to prepare 10% liver tissue homogenate, centrifuging at 4000r/min for 15min, taking supernatant, and determining GSH-Px, T-AOC, SOD activity and MDA content of a liver tissue sample according to a kit specification.
(3) Results of the experiment
From FIGS. 4, 5, 6 and 7, it is clear that after D-galactose injection, the GSH-Px, SOD and T-AOC activities in the serum of the mice were significantly decreased and the MDA content was significantly increased compared to the normal control group. After the traditional Chinese medicine extract, the traditional Chinese medicine probiotic fermentation product and the monomer compound with the structure of the formula (I) are perfused, the GSH-Px and T-AOC activities of the mouse serum are remarkably increased compared with those of a model injury group; compared with a model injury group, after gastric lavage of traditional Chinese medicine extract, traditional Chinese medicine probiotic fermentation product and monomer compound with the structure of formula (I), the activity of SOD is obviously improved; after the traditional Chinese medicine extract, the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure of the formula (I) are perfused, compared with a model injury group, the MDA content is obviously reduced; wherein the activity of the monomer compound SOD with the structure of formula (I) is 1.26 times of that of the model group, the activity of GSP-Px is 1.36 times of that of the model group, the activity of T-AOC is 1.61 times of that of the model group, and the MDA content is 69.6% of that of the model group.
As can be seen from fig. 8, 9, 10, and 11, after D-galactose injection, the mouse liver had a significant decrease in GSH-Px activity, a significant decrease in T-AOC activity, and a significant increase in MDA content, as compared to the model injury group, as compared to the SOD activity and the normal control group; the T-AOC activity of mouse liver in the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of formula (I) is obviously improved compared with that of a model injury group, but is still lower than that of a normal control group after the experiment is finished; compared with the model injury group, the activity of GSH-Px and SOD of mouse liver in the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of formula (I) is obviously improved; compared with the model injury group, the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of the formula (I) obviously reduce the MDA content of the liver of the mouse; in the monomer compound group with the structure of the formula (I), the activity of SOD is 1.73 times that of the model group, the activity of GSP-Px is 1.31 times that of the model group, the activity of T-AOC is increased by 1.74 times that of the model group, and the content of MDA is 69.1% that of the model group.
The experiment shows that the antioxidant effect of the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure of the formula (I) is greater than that of a simple traditional Chinese medicine extract; the traditional Chinese medicine probiotic fermentation product prepared by the method and the monomeric compound with the structure of the formula (I) have more excellent antioxidant effect on the basis of the traditional Chinese medicine extract; in particular to the monomer compound with the structure of formula (I) which is obtained by separation and has stronger antioxidation.
Experimental example 2 evaluation of anti-aging Effect of fermented product of Chinese medicinal probiotic and monomeric compound having structure of formula (I)
(1) The wild type caenorhabditis elegans N2 is cultured at 20 ℃, and randomly divided into 4 groups (the number of each group is not less than 60), wherein each group comprises 3 parallel Control groups, namely a normal Control group (Control), a traditional Chinese medicine extract group (TCM) prepared in comparative example 1, a traditional Chinese medicine probiotic fermentation product group (TCMPM) prepared in example 2 and a monomeric compound group (TPMSC) with a structure of formula (I). The experimental group is pre-cultured for 4 days according to the dosage of 50 mug/mL, the phosphate buffer solution is used for replacing the traditional Chinese medicine probiotics fermentation metabolites in the normal control group, and counting is carried out for 1 time every day until all the worms die. The results are shown in fig. 12, the life of the N2 wild-type nematodes can be significantly prolonged by the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of formula (i), and the life of the nematodes of the traditional Chinese medicine extract group, the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of formula (i) can be respectively prolonged by 17.9%, 25.9% and 34.0% compared with the normal control group.
(2) The method comprises the following steps of culturing N2 wild-type nematodes at 20 ℃, randomly dividing the wild-type nematodes into 5 groups (the number of each group is not less than 60), and randomly dividing each group into 3 parallel Control groups, namely a normal Control group (abbreviated as Control), a model injury group (Par), a traditional Chinese medicine extract group (TCM) prepared in comparative example 1, a traditional Chinese medicine probiotic fermentation product group (TCMPM) prepared in example 2 and a monomeric compound group (TPMSC) with a structure of a formula (I), pre-culturing the experimental group for 4 days according to a dose of 50 mu g/mL, treating the nematodes in the other groups except the normal Control group by using paraquat, replacing the traditional Chinese medicines with phosphate buffer solutions in the normal Control group, counting 1 time every day for traditional Chinese medicine probiotic fermentation products and traditional Chinese medicine probiotic metabolic product monomeric compounds until all worms die. The results are shown in fig. 13, the life of the nematodes after paraquat treatment is significantly reduced, and the life of the nematodes after paraquat treatment is reduced by 23.9%; the service life of the nematodes cultured by the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure of the formula (I) is obviously prolonged, and the service lives of the nematodes in the traditional Chinese medicine extract group, the traditional Chinese medicine probiotic fermentation product group and the monomeric compound with the structure of the formula (I) are respectively prolonged by 10.3%, 13.5% and 23.5%.
(3) Culturing N2 wild type nematodes at 20 deg.C, randomly dividing into 5 groups (each group has no less than 60), each group has 3 parallel Control groups, which are respectively a normal Control group (abbreviated as Control), a model injury group (Par), a traditional Chinese medicine extract group (TCM) prepared in comparative example 1, a traditional Chinese medicine probiotic fermentation product group (TCMPM) prepared in example 2 and a monomeric compound group (TPMSC) with formula (I), meanwhile, the experimental group was pre-cultured for 4 days at a dose of 50. mu.g/mL, except for the normal control group, treating other groups of nematodes with paraquat, replacing traditional Chinese medicine extract, traditional Chinese medicine probiotic fermentation product and monomer compound with formula (I) with phosphate buffered saline solution in normal control group, counting for 1 time every day, culturing for 4 days, and determining in vivo related antioxidant enzyme activity (superoxide dismutase SOD and malondialdehyde MDA) and Reactive Oxygen Species (ROS) content. After the traditional Chinese medicine extract, the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure shown in the formula (I) are pre-cultured and treated by paraquat, the survival rate of the nematodes is recorded after the nematodes are continuously cultured for 4 days. The results are shown in FIGS. 14-16, wherein FIG. 14 is a graph of ROS content measurement, FIG. 15 is a graph of MDA content measurement, and FIG. 16 is a graph of SOD content measurement. After paraquat treatment, the activity of related antioxidant enzymes in the nematode bodies is obviously reduced compared with that of a normal control group, and the content of ROS is obviously increased compared with that of the normal control group; after being pretreated by the traditional Chinese medicine probiotic fermentation product of 50 mu g/mL and the monomer compound of the structure of the formula (I), the activity of the antioxidant enzyme in the nematode in the traditional Chinese medicine probiotic fermentation product group and the monomer compound of the structure of the formula (I) is obviously improved compared with that in a model damage group; for SOD activity, compared with a model damage group, the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of the formula (I) are obviously increased; compared with a model damage group, the ROS content of the traditional Chinese medicine probiotic fermentation product group and the monomer compound group with the structure of the formula (I) is remarkably reduced, wherein in the monomer compound group with the structure of the formula (I), the activity of SOD is 1.26 times that of the model damage group, and the MDA content is 68.8% of that of the model damage group.
The experiments show that the anti-aging effect of the traditional Chinese medicine probiotic fermentation product and the monomeric compound with the structure of the formula (I) is greater than that of a simple traditional Chinese medicine extract; the traditional Chinese medicine probiotic fermentation product obtained by fermentation based on the traditional Chinese medicine extract and the monomer compound with the structure of the formula (I) have more excellent anti-aging effect; in particular to the monomer compound with the structure of formula (I) which is obtained by separation and has stronger anti-aging effect.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (10)
2. a process for the preparation of a compound of formula (i) as claimed in claim 1, comprising the steps of:
(1) taking the traditional Chinese medicine raw materials, and fermenting with probiotics to obtain fermentation liquor;
(2) drying the fermentation liquor to obtain a crude product;
(3) separating the crude product by chromatography to obtain a compound of formula (I);
the traditional Chinese medicine raw materials in the step (1) are traditional Chinese medicine raw materials comprising purple perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaf, mint and gorgon fruit;
the probiotics in the step (1) are selected from one or a mixture of more than two of bifidobacteria, lactobacillus liquid, bifidobacterium adolescentis or bifidobacterium infantis.
3. The preparation method according to claim 2, wherein the specific method of step (1) is: extracting the Chinese medicinal materials with water, and concentrating the extractive solution to obtain concentrated solution; then adding a fermentation nutrient into the concentrated solution; and then adding probiotics to ferment for 24-48 h under the conditions that the temperature is 35-40 ℃ and the pH is 6.5-7.5 to obtain fermentation liquor.
4. The process according to claim 2, wherein the chromatographic technique in step (3) is a preparative HPLC technique; the specific conditions of the preparative HPLC technique are as follows: adopting a reversed phase chromatographic column; selecting an ultraviolet detector, wherein the detection wavelength is 220-230 nm; using a trifluoroacetic acid aqueous solution with the volume percent of 0.1-0.3 as a mobile phase A, using a trifluoroacetic acid acetonitrile solution with the volume percent of 0.1-0.3 as a mobile phase B, wherein the mobile phase A: mobile phase B-78: 22; and (3) collecting the part corresponding to the chromatographic peak for 13.0-13.7 min, concentrating and drying to obtain the compound shown in the formula (I).
5. A traditional Chinese medicine probiotic fermentation product is characterized by comprising a compound shown in a formula (I).
6. The method for preparing the traditional Chinese medicine probiotic fermentation product according to claim 5, characterized by comprising the following steps:
(1) taking the traditional Chinese medicine raw materials, and fermenting with probiotics to obtain fermentation liquor;
(2) drying the fermentation liquor to obtain the traditional Chinese medicine probiotic fermentation product;
the traditional Chinese medicine raw materials in the step (1) are traditional Chinese medicine raw materials comprising purple perilla, astragalus, lily, rhodiola rosea, glossy privet fruit, pseudo-ginseng, ginkgo leaf, mint and gorgon fruit;
the probiotics in the step (1) are selected from one or a mixture of more than two of bifidobacteria, lactobacillus liquid, bifidobacterium adolescentis or bifidobacterium infantis.
7. The preparation method according to claim 5, wherein the specific method of step (1) is: extracting the Chinese medicinal materials with water, and concentrating the extractive solution to obtain concentrated solution; then adding a fermentation nutrient into the concentrated solution; and then adding probiotics to ferment for 24-48 h under the conditions that the temperature is 35-40 ℃ and the pH is 6.5-7.5 to obtain fermentation liquor.
8. Use of a compound of formula (i) as defined in claim 1 or a pharmaceutically acceptable salt thereof or a fermentation product of a probiotic of a traditional Chinese medicine as defined in claim 6 in the manufacture of a medicament or a health product.
9. The use according to claim 8, wherein the medicament is a medicament having antioxidant and/or anti-aging effects;
the health care product has an anti-oxidation effect and/or an anti-aging effect.
10. The use according to claim 9, wherein the medicament or health product comprises a compound of formula (i) or a pharmaceutically acceptable salt thereof or a probiotic fermentation product of a traditional Chinese medicine and a carrier; the mass fraction of the compound of formula (I) or the medicinal salt thereof or the traditional Chinese medicine probiotic fermentation product is 5-95%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911170311.1A CN112521447A (en) | 2019-11-26 | 2019-11-26 | Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with anti-aging effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911170311.1A CN112521447A (en) | 2019-11-26 | 2019-11-26 | Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with anti-aging effect |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112521447A true CN112521447A (en) | 2021-03-19 |
Family
ID=74974614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911170311.1A Pending CN112521447A (en) | 2019-11-26 | 2019-11-26 | Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with anti-aging effect |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112521447A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113875987A (en) * | 2021-09-17 | 2022-01-04 | 无锡弘焕微生态科技有限公司 | Formula food with anti-aging function |
-
2019
- 2019-11-26 CN CN201911170311.1A patent/CN112521447A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113875987A (en) * | 2021-09-17 | 2022-01-04 | 无锡弘焕微生态科技有限公司 | Formula food with anti-aging function |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104435775B (en) | A kind of Traditional Chinese medicinal health-care wine and preparation method thereof | |
CN109316517B (en) | Preparation method and application of fresh ginseng cream | |
CN107296949A (en) | Integration of drinking and medicinal herbs compound formulation and its preparation method and application | |
CN102827750A (en) | Maca health care liquor for improving organism immunity and sexuality | |
CN106244371B (en) | A kind of hypoglycemic rhizoma polygonati grape health care wine and its production technology | |
CN103320295B (en) | Compound wine | |
CN109294835A (en) | A kind of Chinese medicament healthcare wine formula of anti-aging | |
CN105294811A (en) | Method for preparing ganoderma lucidum karst triterpenic acid and ganoderma lucidum karst polysaccharide with Nyingchi ganoderma lucidum karst as material | |
CN110664906B (en) | Preparation method of health food with blood sugar reducing function | |
CN105532991A (en) | Composite dark green tea with functions of maintaining beauty and caring skin and preparation method thereof | |
CN103027139A (en) | Health tea suitable for use in all seasons | |
CN101720826A (en) | Five-flower tea for clearing heart and quieting spirit | |
CN112521447A (en) | Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with anti-aging effect | |
CN104490712A (en) | Traditional Chinese medicine composition with anti-aging effect and application thereof in cosmetics | |
CN111358922A (en) | Traditional Chinese medicine composition for warming and invigorating kidney yang and improving cold constitution and preparation method and application thereof | |
CN114848727B (en) | Preparation method and application of American ginseng paste | |
CN102961611A (en) | Health-care medicinal liquor and preparation method thereof | |
CN101219180A (en) | Health care wine and its processing method | |
CN105410243A (en) | Healthcare tea for health preservation in four seasons | |
CN107158299B (en) | Composition with function of enhancing learning memory and preparation method thereof | |
CN104337920A (en) | Traditional Chinese medicine composition for improving sleep quality | |
CN111870630A (en) | Medicine formula for enhancing resistance and immunity and preparation process | |
CN109852519A (en) | A kind of health liquor and preparation method thereof | |
CN104116908A (en) | A traditional Chinese medicine decoction for treating arrhythmia | |
CN103609960A (en) | Nutritive porridge for preventing alopecia and processing technology of nutritive porridge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210319 |